![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Gilead’s HIV Drug Approved in China
Gilead’s HIV Drug Approved in China
![Purple_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Purple_Approved_Stamp.gif?t=1576639773&width=430)
The China National Medical Products Administration has approved Gilead’s fixed-dose combination HIV treatment Descovy (emtricitabine and tenofovir alafenamide).
Descovy is indicated in China for treating, in combination with other antiretroviral agents, HIV-1 patients aged 12 and older that weigh at least 77 lbs. Its approval stems from results of two Phase 3 studies that met their primary objectives of non-inferiority compared to a Stribild regimen.
Descovy comes with a boxed warning in the U.S. regarding the risks of post treatment acute exacerbation of hepatitis B. It received FDA and European Commission marketing approval in 2016.
Upcoming Events
-
21Oct